Introduction
Allogeneic hematopoietic SCT (HSCT) is increasingly considered an option in refractory or relapsing lymphoma. [1] [2] [3] Advances in protective care and the introduction of non-myeloablative conditioning regimens have extended the range of patients eligible for this treatment modality. 4 Chemotherapy regimens used to treat lymphoma have also evolved. The addition of monoclonal antibodies such as rituximab to standard cytoreductive agents has become common practice. 5, 6 As rituximab is widely used as part of first-line or reinduction regimens in patients with mature B-cell neoplasms, the majority of patients undergoing allogeneic transplantation for B-cell lymphomas today have a history of rituximab pretreatment.
Rituximab, a chimeric monoclonal antibody directed against CD20, has an elimination half-life of 10 days and may therefore remain in circulation for several months after the last administration. 7 As CD20 is expressed on most B-cell maturation stages, patients treated with rituximab in a non-transplant setting typically have a profound B-cell lymphopenia in their peripheral blood for 6-12 months, and B-cell counts begin to rise only after the antibody has been cleared.
Patients undergoing HSCT after a first-line or reinduction treatment containing rituximab might therefore be at risk of impaired B-cell reconstitution, due to in vivo depletion of mature B cells and/or B-cell precursors if rituximab is still in circulation at the time of graft infusion. In this study, we analyzed B-cell reconstitution and immunoglobulin levels of 12 lymphoma patients undergoing allogeneic HSCT after prior treatment with rituximab. Results were compared to a cohort of consecutive patients receiving transplants for myeloid malignancies in the same time period without rituximab pretreatment. We found that patients with lymphoma and prior treatment with rituximab had a profoundly delayed B-cell recovery and decreased levels of immunoglobulins up to 24 months after transplantation.
Patients and methods
This is a retrospective single-center study. Outcome of 12 consecutive patients with B-cell lymphoma and preceding treatment with rituximab receiving T-cell replete allogeneic peripheral blood SCT between 2000 and 2007 was analyzed. All patients gave written informed consent. Five patients were transplanted for follicular lymphoma, three for diffuse large B-cell lymphoma, and two patients each for marginal cell lymphoma and mantle cell lymphoma. Ten patients were transplanted from an HLA-identical sibling, two patients from a 10/10 HLA-matched unrelated donor. A cohort of 12 consecutive patients receiving allogeneic transplantation for myeloid malignancies was used as controls. Patients in both cohorts were wellmatched for age, sex and donor type. Incidence and severity of acute and chronic GVHD were comparable in the two cohorts (Table 1) . Patients in both the groups received i.v. immunoglobulin substitution if IgG levels were below 5 g/l.
Conditioning in the lymphoma cohort consisted of BEAM (BCNU, etoposide, cytarabine, melphalan), fludarabine and single-dose TBI (2 Gy) as described previously. GVHD prophylaxis consisted of CsA and mycophenolate mofetil (for 30 days post transplant) in the lymphoma group; in the control group, GVHD prophylaxis was with CsA and a short course of MTX at days 1, 3 and 6. Firstline treatment of acute GVHD grade XII in both cohorts was with 2 mg per kg body weight i.v. methylprednisone.
No patient required a second line of GVHD treatment. Treatment of chronic GVHD was with oral prednisone and CsA in all the patients.
PBL subsets (CD19 þ B cells, CD4 þ /CD3 þ T cells, CD8 þ /CD3 þ T cells and CD56 þ /CD3À NK cells) were analyzed serially (pretransplant and at 1, 3, 6, 12 and 24 months post transplant) by flow cytometry. Immunoglobulin levels (IgG, IgA and IgM) were assessed by nephelometry pretransplant and at 3, 6, 12 and 24 months post transplant. Absolute numbers of PBL subsets and immunoglobulin levels were compared between patients with rituximab pretreatment and those without by MannWhitney U-test. Two sided P-values o0.05 were considered significant.
Results
All patients had stable engraftment. Time to engraftment was 13 ( ± 1) days in the lymphoma group vs 15 ( ± 1) days in the control cohort. All patients were alive at the last follow-up. Median follow-up was 38 months (range 1-83 months). Time since last rituximab treatment was 6 months (median, range 1-12 months).
B-lymphocyte reconstitution is delayed in lymphoma patients with rituximab treatment before HSCT Total number of peripheral blood CD19 þ B cells in lymphoma patients receiving allogeneic transplantation Median interval between the last administration of rituximab and allogeneic transplantation was 6 months. Patients receiving the last rituximab administration more than 6 months before HSCT had a faster B-cell reconstitution than patients receiving rituximab in the 6 months preceding HSCT (median number of B cells at 6 months 113 vs 0 Â 10 6 /l; median number of B cells at 24 months 307 vs 75 Â 10 6 /l in patients with a longer and shorter interval, respectively).
Immunoglobulin levels are reduced in patients with rituximab in pretreatment Immunoglobulin levels pretransplant in patients with rituximab in pretreatment were significantly lower as compared to the control group at the time of transplant: IgA 0.48 g/l (median, range 0-1.1 g/l) vs 1.6 g/l (median, range 0.3-4.7 g/l), Po0.001; IgG 3.7 g/l (median, range 1.9-8.5 g/l) vs 9.2 g/l (median, range 7.4-18.3 g/l), Po0.001 and IgM 0.29 g/l (median, range 0-5.0 g/l) vs 0.70 g/l (median, range 0.1-1.4 g/l), P ¼ 0.02. These differences were observed throughout the first 12 months post transplant (Figures 2a-c) and were more prominent for IgA and IgM than for IgG. At 2 years of follow-up, the levels of immunoglobulins were no longer statistically different. However, in four patients, IgG levels were still below 4 g/l and these patients were hence substituted with intravenous immunoglobulins (IVIG).
Infectious complications
Two lymphoma patients experienced late severe bacterial infections. One patient was diagnosed 8 months post transplant with ureaplasma ureolyticum septicemia and arthritis. CD19 þ B cells were not detectable at this time, immunoglobulin levels were IgG 0.39 g/l, and IgM and IgA were not detectable. 9 The second patient suffered 
GVHD
Cumulative incidence of both acute GVHD 4grade 2 (50 vs 33.3%, P ¼ 0.4) and chronic extensive GVHD (41.7 vs 33.3%, P ¼ 0.78) was similar in both the groups.
Discussion
We show in a population of patients treated for lymphoma with allogeneic HSCT a profound and long-lasting deficit in humoral immunity. Although this study lacked demonstration of circulating antibody at the time of transplantation, the complete absence of B cells at the time of transplant strongly suggests that anti-CD20 antibody was still present in circulation at the time of stem cell infusion. We found no correlation between the B-cell count pretransplant and the time since last administration of rituximab; however, interval between the last administration of the antibody and the transplant was 6 months with a range of up to 1 year, which is well within the time frame during which rituximab can induce complete peripheral B-cell depletion. 10 As CD20, the target antigen of rituximab, is expressed early in the ontogeny of B cells (starting with pre-B-cells), it is conceivable that circulating rituximab depletes B cells and their precursors at the time of graft infusion. This might explain the marked delay in B-lymphocyte recovery and the reduced level of immunoglobulins in HSCT patients with a history of rituximab treatment.
As plasma cells are CD20-negative, rituximab treatment in a non-transplant setting is usually not associated with a significant decrease of immunoglobulins or an increased predisposition for bacterial infections. 11 In our study, we demonstrate long-lasting and profound B-cell lymphopenia and a significant reduction of immunoglobulin levels. As stem cell transplant recipients are at an inherently high risk for infectious complications, it is difficult to assess a possible causal relationship between B-cell lymphopenia and bacterial infections. However, a contribution of B-cell lymphopenia and hypogammaglobulinemia to the two episodes of severe late bacterial infections described appears likely. These data underline the importance of monitoring immunoglobulin levels post transplant.
In patients receiving rituximab in a non-transplant setting or before autologous HSCT, late-onset neutropenia has been described in up to 25% of patients. 12 In our cohort, no such complications were noted. All patients achieved rapid neutrophil engraftment and had a stable graft function in the post-transplant period.
This study has several limitations. Patient number was small. Serum levels of rituximab were not measured, which would have provided direct evidence for circulating antibody at the time of graft infusion, and our control group had myeloid malignancies and another conditioning regimen. However, we believe that the complete absence of peripheral blood B-lymphocytes in the majority of patients provides a reasonable surrogate marker. In addition, we noted a negative correlation between interval from last rituximab administration to allogeneic transplantation and delay of B-cell reconstitution, supporting the notion that higher levels of circulating rituximab lead to a more profound and prolonged B-cell depletion after transplantation. As virtually all patients with B-cell lymphoma receive rituximab before allogeneic transplantation, we had no control group of patients with lymphoma who had not been treated with rituximab. Still, reconstitution of the non-B-cell lymphocyte subsets and rates of GVHD were comparable. We therefore believe that the differences seen in the recovery of B cells were not the results of disparities in underlying disease or conditioning regimen but a late effect of rituximab pretreatment. In conclusion, our report shows profoundly delayed B-cell reconstitution and decreased immunoglobulin levels in a cohort of patients with refractory or relapsing lymphoma treated with allogeneic HSCT after prior treatment with rituximab.
